Search Results
Aug 12, 2026, 16:05 ET Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
proprietary nafamostat formulation for direct IV infusion that may be investigated and developed for the treatment of acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), acute pancreatitis or as an anti-viral treatment, amongst other potential targets.About the
More news about: Talphera, Inc.
Aug 10, 2026, 10:01 ET Ventilators Market worth $3.10 billion by 2031 - Exclusive Report by MarketsandMarkets™
market. ICU ventilators are life-saving to treat critically ill individuals, particularly those with acute respiratory distress, severe pneumonia, ARDS, and post-operative conditions requiring constant respiratory support. The prevalence of respiratory disease, aging population, and rising number of
More news about: MarketsandMarkets
Jul 30, 2026, 08:30 ET Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).RYBREVANT with Carboplatin and PemetrexedIn MARIPOSA-2 (n=130), the most common ARs (≥20%)
More news about: Johnson & Johnson
Jul 09, 2026, 08:05 ET FDA Approves ENNUMO™ (pegfilgrastim-pccg), Accord BioPharma's Second Pegfilgrastim Biosimilar to NEULASTA® (pegfilgrastim)
Syndrome: Acute respiratory distress syndrome (ARDS) can occur in patients receiving pegfilgrastim products. Evaluate patients for ARDS who develop fever, lung infiltrates or respiratory distress after receiving ENNUMO. Discontinue ENNUMO in patients with ARDS.Serious Hypersensitivity Reactions: Serious
More news about: Accord BioPharma
Jun 22, 2026, 14:11 ET Draeger, Inc. Announces FDA Clearance for Evita V800 Software 3.10 - Advancing Ventilation Technology
software release, the V800 provides additional features to help enhance mechanical ventilation of patients suffering from pulmonary disease such as ARDS.Decelerating flow during volume control ventilation provides clinician-controlled flow to match patient demand with recommended
More news about: Draeger
Jun 03, 2026, 14:25 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
hlavy, hypoxia, nevoľnosť a zvracanie. Medzi potenciálne život ohrozujúce komplikácie CRS patria srdcová dysfunkcia, syndróm akútnej respiračnej tiesne (ARDS), neurologická toxicita, zlyhanie obličiek a/alebo pečene a diseminovaná intravaskulárna koagulácia (DIC).Na zníženie rizika CRS sa má liek
More news about: Amgen
Jun 03, 2026, 10:21 ET KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ
niedotlenienie, nudności i wymioty. Potencjalne powikłania zagrażające życiu obejmują: zaburzenia czynności serca, ostry zespół niewydolności oddechowej (ARDS), neurotoksyczność, niewydolność nerek i/lub wątroby oraz rozsiane wykrzepianie wewnątrznaczyniowe (DIC).Preparat IMDELLTRA®
More news about: Amgen
Jun 02, 2026, 09:45 ET Piedmont Atlanta Hospital Reaches Milestone for Use of Extracorporeal Membrane Oxygenation
membrane oxygenation (ECMO) in the critical care setting on patients suffering from the combination of COVID-19 and Acute Respiratory Distress Syndrome (ARDS).Ten years ago, the adult ECMO program at Piedmont Atlanta was the first in Georgia to be recognized as a Center of Excellence by the Extracorporeal
More news about: Piedmont Healthcare
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).RYBREVANT® with Carboplatin and PemetrexedIn MARIPOSA-2 (n=130), the
More news about: Johnson & Johnson
May 29, 2026, 14:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).RYBREVANT® with Carboplatin and PemetrexedIn MARIPOSA-2 (n=130), the
More news about: Johnson & Johnson
May 13, 2026, 16:05 ET Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
proprietary nafamostat formulation for direct IV infusion that may be investigated and developed for the treatment of acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), acute pancreatitis or as an anti-viral treatment, amongst other potential targets.About the
More news about: Talphera, Inc.
May 13, 2026, 13:43 ET Journal of Independent Medicine Releases New Issue Featuring Major Review on Autism Spectrum Disorder and Expanding Global Contributions to Honest Medicine
Mechanical Ventilation in Severe COVID-19 ARDS: A Fatal CaseSantiago M. Herrero, Jesús A. Alvarez-FernándezDescribes a fatal airway complication associated with prolonged mechanical ventilation in severe COVID-19 ARDS.Chlorine Dioxide as an Adjunctive
More news about: Independent Medical Alliance
May 04, 2026, 17:04 ET Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)
Results from a randomized, placebo-controlled trial demonstrate that CK0802 Tregs are a safe and highly effective treatment for critically ill COVID-19 ARDS patients, requiring mechanical ventilation and vasopressor support, thought to be driven by severe "cytokine storm" inflammation, like that seen in
More news about: Cellenkos, Inc.
May 04, 2026, 16:40 ET Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)
Results from a randomized, placebo-controlled trial demonstrate that CK0802 Tregs are a safe and highly effective treatment for critically ill COVID-19 ARDS patients, requiring mechanical ventilation and vasopressor support, thought to be driven by severe "cytokine storm" inflammation, like that seen in
More news about: Cellenkos, Inc.
Apr 27, 2026, 08:00 ET RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
and Fatty Liver Disease) following prior publication of promising results continuesPrograms in Ebola, acute respiratory distress syndrome (ARDS, COVID-19 and Influenza continue to seek to address important markets worth multiple hundreds of millions of dollarsRHB-20410:RHB-204
More news about: RedHill Biopharma Ltd.
Apr 21, 2026, 10:01 ET Extracorporeal Membrane Oxygenation Market to Reach $952.2 Million by 2035, Growing at 5% CAGR
people are using it in intensive care units. The market is growing because more people are getting conditions like acute respiratory distress syndrome (ARDS), cardiogenic shock, and neonatal respiratory failure. For example, the rise in the number of people with chronic obstructive pulmonary disease (COPD)
More news about: Allied Market Research
Apr 15, 2026, 12:02 ET Pressure Ulcers Market to Reach $5.6 Billion by 2031, Growing at 4.2% CAGR - Allied Market Research
COVID-19 on pressure ulcer incidence: The pandemic created a notable secondary effect on the market patients with acute respiratory distress syndrome (ARDS) requiring prone positioning for 12–16 hours showed elevated risk of pressure injuries, temporarily boosting demand for specialized wound care products
More news about: Allied Market Research
Mar 25, 2026, 08:30 ET Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
proprietary nafamostat formulation for direct IV infusion that may be investigated and developed for the treatment of acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), acute pancreatitis or as an anti-viral treatment, amongst other potential targets.About Talphera,
More news about: Talphera, Inc.
Mar 23, 2026, 08:30 ET Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
proprietary nafamostat formulation for direct IV infusion that may be investigated and developed for the treatment of acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), acute pancreatitis or as an anti-viral treatment, amongst other potential targets.About the
More news about: Talphera, Inc.
Mar 18, 2026, 16:05 ET Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026
shock, vasopressor therapy, extracorporeal membrane oxygenation (ECMO), hepatorenal syndrome (HRS), COVID-19, and acute respiratory distress syndrome (ARDS). As an investigator, he has enrolled approximately 300 critically ill or hospitalized patients into more than a dozen investigator-initiated or industry-sponsored
More news about: Talphera, Inc.
Mar 02, 2026, 08:30 ET Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial
shock, vasopressor therapy, extracorporeal membrane oxygenation (ECMO), hepatorenal syndrome (HRS), COVID-19, and acute respiratory distress syndrome (ARDS). As site principal investigator or an investigator, he has enrolled approximately 300 critically ill or hospitalized patients into more than a dozen
More news about: Talphera, Inc.
Feb 19, 2026, 17:00 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).RYBREVANT® with Carboplatin and PemetrexedIn MARIPOSA-2 (n=130), the
More news about: Johnson & Johnson
Feb 18, 2026, 07:30 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).RYBREVANT® with Carboplatin and PemetrexedIn MARIPOSA-2 (n=130), the
More news about: Johnson & Johnson
Feb 17, 2026, 11:00 ET FDA Approves FILKRI™ (filgrastim-laha), Accord BioPharma's Biosimilar to NEUPOGEN® (filgrastim)
Acute Respiratory Distress Syndrome (ARDS): ARDS has been reported in patients receiving filgrastim products. Evaluate patients who develop fever and lung infiltrates or respiratory distress for ARDS. Discontinue FILKRI in patients with ARDS. Serious Allergic Reactions:
More news about: Accord BioPharma
Feb 17, 2026, 08:00 ET FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).RYBREVANT® with Carboplatin and PemetrexedIn MARIPOSA-2 (n=130), the
More news about: Johnson & Johnson